2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 265-268
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Biological Therapies, Checkpoint Inhibitor, Biological Processes, Apoptosis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, CLL, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

681 Differential and persistent remodeling of the lymph node Stromal–Immune niche by BTK and BCL-2 inhibitors in CLL and Richter Transformation

Juliet Meir, MD, Bruce Huang, BS2, Kelly Wong, BS3, Lena Tran4, Yu-Ju Chen, MD5, Peace Olutoye, MD6, Xiao Yan, MD, PhD7, Dimitar Efremov, MD,PhD8, Nicholas Chiorazzi, MD9, Shih-Shih Chen, PhD10
1 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
2 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
3 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
4 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
5 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
6 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
7 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
8 International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy
9 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States
10 Feinstein Institutes for Medical Research Northwell, Manhasset, New York, United States

The lymph node (LN) microenvironment is critical to chronic lymphocytic leukemia (CLL) progression and transformation to Richter syndrome (RS). Recent study using single-cell and spatial transcriptomics identified specialized fibroblast populations within CLL LNs: CCL19-expressing fibroblasts are enriched in proliferation centers, CCL21-expressing fibroblasts form a ring around the central MYC-positive core, and CXCL12 is prominent in subcapsular/B cell-associated and mural/perivascular fibroblasts. These spatially organized chemokine niches support malignant B-cell retention and proliferation. 

Our prior work defined a CXCR4DimCD5Bright proliferative fraction (PF), enriched in newly born CLL cells, and a quiescent CXCR4BrightCD5Dim resting fraction. PF cells display strong CXCR4 signaling and integrin signatures that promote stromal adhesion and retention. Although BTK inhibitors (e.g., ibrutinib, acalabrutinib) eliminate the PF, their effects on stromal and immune compartments remain unclear. Thus, this study aimed to investigate the distinct effects of these drugs on stromal cell function and T-cell dynamics in both CLL and RS contexts, and to determine if these effects persist after drug and tumor removal.

We first established a co-culture system of human LN fibroblasts (HLFs) with patient-derived RS cell lines (RS9737, RS1316, and RS1050) or accelerated primary CLL patient cells (CLL2443 and CLL0625). HLFs enhanced tumor-cell survival and lymphotoxin production, while tumor exposure induced distinct fibroblast subtypes expressing CCL19, CCL21, and CXCL12. These tumor-exposed HLFs reshaped the immune landscape by promoting CD4+CD25+FOXP3+ regulatory T cell (Treg) expansion and suppressing CD8+Perforin+Granzyme B+ cytotoxic T cells, thereby fostering T-cell exhaustion. 

We next evaluated 100 nM venetoclax and 1 µM ibrutinib or acalabrutinib in HLF and RS co-cultures. All treatments reduced tumor viability, but only venetoclax partially reversed RS9737-induced stromal reprogramming, increasing PDPN and LTβR and restoring HLF morphology. BTK inhibitors had little effect on RS-associated stromal changes but altered HLF morphology in CLL co-cultures, with progressive thinning after ibrutinib; acalabrutinib reduced CCL19 without affecting other CAF markers. Minimal effects in HLF monocultures indicate that these stromal changes are driven primarily by tumor–stroma interactions rather than direct drug action. 

To assess the immune consequences of treatment-exposed stroma, tumor cells were removed, HLFs were washed, and autologous CLL T cells were added. BTKi treatment resulted in the reduction of Tregs and CD8 T cell activation. Similar results were seen in the Richter’s setting using healthy T cells. To further mimic the heavy-treatment history typically seen in Richter’s patients, we performed “scar experiments” to demonstrate whether drug exposure left a persistent stromal imprint. To do this, RS-HLF co-cultures were first treated with BTK inhibitors for 3 days, and subsequently with venetoclax for 3 days. These heavily treated RS-HLFs were then examined for their expression of CCL19, CXCL12, FAP, aSMA and LTbR by flow cytometry. Interestingly, only CCL19-secreting fibroblasts were decreased but led to depletion of Tregs and cytotoxic T cells, highlighting that the initial treatments profoundly shape stroma and subsequent T-cell responses.

Finally, we validated these findings in NSG xenografts using Matrigel containing HLFs, RS cells, or both. HLFs injected alone localized mainly to the bone marrow and peritoneal cavity, whereas co-injection with RS cells redirected HLFs to the spleen and Matrigel tumor mass and increased CCL19 and CXCL12 production. RS cells injected alone localized mainly to the spleen and Matrigel mass, while HLF co-injection shifted them toward the spleen and peritoneal cavity. BTK inhibition excluded tumor cells from tissue niches and promoted stromal recovery. 

In conclusion, our work demonstrated for the first time that CLL LN fibroblasts actively regulate tumor survival, chemokine organization, and immune suppression in CLL and RS. Targeted therapies differentially remodel the tumor–stroma–immune circuit and can leave a persistent stromal scar that shapes later T-cell responses. These findings suggest that treatment sequencing should account for tumor-specific signaling programs and their effects on the residual stromal–immune niche, particularly when BTK inhibitors are followed by immunotherapy. 

Juliet Meir, MD: No relevant conflicts of interest to declare.